Some patients with HCC haven't abnornormal des-gamma-carboxy prothrombin and alpha-fetoprotein levels

Panminerva Medica

Volumn 51, Issue 2, 2009, Pages 133-134

  Bertino, G ^a   Ardiri, A M ^a   Santonocito, M M ^a   Boemi, P M ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFP PROTEIN, HUMAN; ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; PROTEIN PRECURSOR; PROTHROMBIN;

BLOOD; CANCER STAGING; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; SENSITIVITY AND SPECIFICITY; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PREDICTIVE VALUE;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; SENSITIVITY AND SPECIFICITY; BIOMARKERS;

EID: 72949112674     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (12)

1. Kim do Y, Paik YH, Ann SH, Youn YJ, Choi JW. Kim JK et al. PIVKA- II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007;72(Suppl l):52-7.
2. Bertino G, Ardiri AM, Boemi PM, Ierna D, Interlandi D, Caruso L et al. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma. Panminerva Med 2008;50:221-6)
3. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001;5:145-59.
4. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-5.
5. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000;95: 1036-40.
6. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ et al. Lok AS Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in ame- rican patients. Hepatology 2003;37:1114-21.
7. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007;3:79-87.
8. Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med 2007;45:1169-79.Review.
9. Llovet JM, Fuster J, Bruix J.The Barcelona approach: diagnosis, staging and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10:S115-120.
10. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology. 2004 Nov; 127(5 Suppl 1):S 113-9. Review
11. Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S et al. Utility of lens culinaris agglutinin-reactive fraction of alpha- fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009;7:104-13.
12. Biasiolo A. Chemello L. Quarta S. Cavalletto L, Bortolotti F, Caber- lotto C et al. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. Viral Hepat 2008;15:246-9.